الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Background: Colorectal cancer is one of the most common cancers worldwide, with the highest incidence rates in western countries. The detrimental side effects of clinically approved anticancer drugs designed for colorectal cancer treatment highlight an urgent need for safer chemotherapeutic drugs. This study was designed to investigate potential protective effect of nilotinib in colorectal cancer. Method: Forty Wistar male rats were divided into Control group (n=6): rats receiving a standard diet, DMH/HFD group (n=12): rats receiving DMH (20 mg/kg) once weekly and HFD daily, Nilotinib group (n=12): rats receiving DMH (20 mg/kg) once weekly, HFD and nilotinib (10 mg/kg) daily and Tenofovir group (n=10): rats receiving DMH (20 mg/kg) once weekly, HFD and tenofovir (50 mg/kg) daily. After 24 weeks, rats were sacrificed, blood was collected and the colorectum was excised from each rat. After that, the colorectum was cut into two halves; one half was fixed in 10% paraformaldehyde prior to processing into paraffin blocks for further histological and immunohistochemical examination of PCNA and Bcl-2. The other half was transferred immediately to -80C for homogenization and further biochemical analysis of oxidative stress markers and ELISA assay of Cyclin D1 and INF-. Results: Treatment with nilotinib and tenofovir significantly down regulated colonic oxidative stress and INF-. Moreover, tenofovir decreased cell proliferation. Conclusion: our study illuminates the promising prophylactic potential of nilotinib and tenofovir against experimentally-induced CRC that can be considered in the future for more investigation in order to prevent/treat colorectal canc.